NeurologyLive® Friday 5 — May 20, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 20, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Mind Moments™ Episode 64: Genetics, Advocacy, and Big Data in ALS

Mind Moments, a podcast from NeurologyLive®, brings you an exclusive interview with Matthew B. Harms, MD, on the progress that the field has seen in recent years in improving the genetic understanding of amyotrophic lateral sclerosis (ALS) and the role that big data can play in care, as well as his perspective on the impact that advocacy efforts have had on these advances.

2: Peer Exchange: ON Time vs OFF Episodes in PD

In Episode 2 of the NeurologyLive® Peer Exchange, "Considerations for the Maintenance of ON Time in Parkinson Disease," Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, define the difference between ON time and OFF episodes for patients with Parkinson disease.

3: NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

4: Connecting ALS: How New Drug Coverage Decisions Are Made

In this episode of the Connecting ALS podcast from the ALS Association, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.

5: Peer Exchange: Innate and Adaptive Immunity and BTK Inhibitors for Multiple Sclerosis

In Episode 2 of this NeurologyLive® Peer Exchange series, "Immune Response in the Management of MS," Barry A. Hendin, MD, and Ahmed Z. Obeidat, MD, PhD, discuss innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).

—————————————————